Full-Time
Data Scientist - Data Product
International Data Science
Posted on 6/19/2025
Flatiron Health
1,001-5,000 employees
Cancer-focused EHR platform for real-world data
No salary listed
Berlin, Germany
In Person
 Data & Analytics (1) |
|---|
- BS or MS from a technical field of study (e.g. data science, engineering, computer science, mathematics, applied statistics, health economics, etc.) with 3-6 years of relevant experience
- Proficient in SQL and Python
- Strong data empathy and enjoy the process of exploring and developing a deep understanding of new data sources
- Understanding of key statistical concepts and the ability to generate and interpret statistical analyses
- Clear and confident communicator who can break down complex data analyses to tell a compelling story
- Self-starter with a strong sense of ownership who can independently prioritize and enjoys coming up with innovative solutions to challenging problems
- Passionate about the mission to improve cancer care through data and technology
- Enjoy working in a fast-paced startup-like environment
- Proficient in English and German
- Become a subject matter expert on our data and its capabilities
- Work closely with a cross-functional team (e.g., product managers, software engineers, oncologists, clinical data specialists) to develop new real-world data products
- Establish strong relationships with key stakeholders at our partner sites and collaborate with them to develop a deep understanding of their data
- Conduct exploratory analyses to inform our approaches to source data ingestion from partners
- Conduct data cleaning and define business logic to transform data into Flatiron’s common data model
- Collaborate with software engineers to implement data pipelines
- Provide analytic support and create custom data outputs for cross-functional teams such as our team of clinical experts
- Prior experience in healthcare
- Experience working in DBT, Snowflake or are excited to learn
Flatiron Health focuses on cancer care with a specialized Electronic Health Record (EHR) platform. It helps community oncologists, academic institutions, hospitals, life sciences researchers, and regulatory bodies manage patient information, share data, and run real-world data-driven studies. The product works by providing a cancer-specific EHR and real-time data integration that connects various stakeholders to enable smarter research and better patient outcomes. It differentiates itself through its narrow focus on oncology, real-world data capabilities, and collaboration across providers, researchers, and regulators, supported by a strong emphasis on data quality (e.g., recognition like the American Cancer Society Data Impact Award). The company aims to improve cancer care and accelerate research by turning real-world data into actionable insights and enabling evidence generation for new treatments.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$2.2B
Headquarters
New York City, New York
Founded
2012
Simplify's Take
What believers are saying
- FDA renews five-year RWE collaboration with Flatiron Health.
- Presents breast cancer research at SABCS 2025 symposium.
- Partners with Veeva and NRG to streamline oncology trials.
What critics are saying
- Paradigm acquires research business, eroding trial revenue.
- Roche antitrust scrutiny forces RWE assets divestiture.
- Veeva integration commoditizes data services for biopharma.
What makes Flatiron Health unique
- OncoEMR integrates Abbott's tests for 1,600 cancer centers.
- VALID Framework validates AI-extracted oncology data peer-reviewed.
- Launches AI-powered prostate datasets for 400,000 patients globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Work/life autonomy via flexible work hours and flexible paid time off
Generous parental leave (16 weeks for either parent)
Transition back to work program following parental leave
Child and caregiver travel benefits for new parents
Backup child care
Weekly meditation sessions
Flatiron-sponsored fitness classes
Weekly massages and manicures available onsite (employee funded)
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Abbott Laboratories has integrated its Precision Oncology portfolio into Flatiron Health's OncoEMR platform, giving over 1,600 community cancer centres and 4,700 providers direct access to tests including Oncotype DX and OncoExTra within their clinical workflows. The integration allows clinicians to order and receive cancer diagnostic results without leaving their electronic medical records system. This follows Abbott's recent integration of its Libre continuous glucose monitoring data into Epic's health record system, part of a broader strategy to embed its products into clinical workflows. Whilst the move may enhance test adoption and streamline administrative tasks, analysts suggest it is unlikely to significantly shift Abbott's near-term investment narrative, which remains centred on its core devices business and managing margin pressure from tariffs and foreign exchange headwinds.
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR(R) platform. * 1 hr ago PR Newswire ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 * Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisions * Allows oncologists to order tests and view results directly in the clinical workflow ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ - Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR(R), Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, oncology providers can now digitally order Abbott tests - individually or in combination - and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score(R), OncoExTra(R), Oncodetect(R), and Riskguard(R) tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care. The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place. "We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster - from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care." "For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Its 122,000 colleagues serve people in more than 160 countries. Connect with Mycarrollcountynews at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, Mycarrollcountynews continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. SOURCE Abbott
Flatiron Health has launched AI-powered prostate cancer datasets spanning Germany, the UK and the US, encompassing records of nearly 400,000 patients. The company is the first to deliver global real-world data in this oncology indication, using proprietary AI and large language models. The Panoramic datasets provide source-level electronic health record data built on a common data model, enabling researchers to analyse patient outcomes and treatment patterns across markets. The datasets include prostate-specific antigen values, PET scan data and genetic information across the patient journey. Founded over a decade ago, Flatiron plans to expand with breast cancer and non-small cell lung cancer datasets in 2027. The company is an independent affiliate of the Roche Group and maintains partnerships with clinical sites across its operating regions.
Paradigm Health has acquired Flatiron Health's clinical research business, creating the largest oncology research network in the United States. The deal includes Flatiron's tech-enabled research network and clinical research solutions, alongside a multi-year collaboration between the companies. The acquisition expands Paradigm Health's network to include over 25 academic medical centres and health systems, plus access to nearly 100 community oncology practices nationwide. The combined network reaches more than 2.4 million patients across the United States. The partnership aims to transform clinical trial conduct and broaden patient access to trials, particularly in rural and community-based practices. The collaboration is designed to maximise benefits for healthcare providers, trial sponsors and patients across the US and globally.
Flatiron Health announces research to be presented at the 2025 San Antonio Breast Cancer Symposium. December 2025 Flatiron's research at SABCS 2025 unlocks breast cancer insights through integrated data, analytics, and expertise. Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron's breast cancer solutions. "Breast cancer is the most common cancer in women worldwide, and every patient's journey raises critical questions - about treatment effectiveness, biomarker-driven approaches, clinical outcomes, and real-world access," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "At Flatiron, we've built a comprehensive, integrated ecosystem of breast cancer solutions that serve every stage of the oncology development life cycle and our research at SABCS demonstrates that when you have the right data infrastructure, analytics, and clinical expertise working together, you can answer virtually any question about breast cancer care and outcomes." Research highlights include: * A Spotlight poster presentation leveraging the Flatiron Health - Caris Life Sciences Clinical-Molecular Database, the largest and most robust multimodal dataset of its kind, to identify key genetic alterations and expression changes linked to CDK4/6i treatment resistance. * A Spotlight poster presentation utilizing large language models to explore the real-world use of GLP-1 medications among breast cancer patients and their potential impact on treatment outcomes. * Multiple posters using Flatiron's Panoramic breast cancer dataset to answer critical research questions on treatment patterns and the effectiveness of novel treatments in improving overall survival and progression-free survival in large, representative patient cohorts. Learn more about its presence on Flatiron.com and follow Flatiron Health on X and LinkedIn for more updates from #SABCS25. Abstracts and Poster Presentations Personalized acquired CDK4/6i resistance: Associations with baseline characteristics like obesity in real-world (RW) clinical-multiomics data Spotlight Poster Presentation Kristin M. Zimmerman Savill, Lilia Bouzit, Noelle Liao, Cheryl Cho-Phan, Simon Papillon-Cavanagh Author Affiliations: Caris Life Sciences, Flatiron Health Presentation Number: PD3-02 Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer Presentation Date/Time: Wednesday, December 10, 2025, 7:33 AM - 7:36 AM Location: 302 ABC Racial/ethnic inequities in access to novel therapies and outcomes in triple negative breast cancer Spotlight Poster Presentation Olive M. Mbah, Gene G. Ho, Catherine Keane, Aaron Dolor, Cleo Ryals Presentation Number: PD1-06 Poster Spotlight 1: Addressing breast cancer disparities and treatment related toxicities Presentation Date/Time: Wednesday, December 10, 2025, 7:45 AM - 7:48 AM Location: Hemisfair 3 Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer Spotlight Poster Presentation Cleo A. Ryals, Auriane Blarre, Blythe Adamson, Daniel Bower, Gene G. Ho, Olive Mbah, Selina Radlein, Erin Fidyk, Fatima Cody Stanford, Aaron B. Cohen Author Affiliations: Massachusetts General Hospital, Flatiron Health Presentation Number: PD8-08 Poster Spotlight 8: Beyond the Scale- Obesity and GLP-1 Therapies in Breast Cancer Presentation Date/Time: Thursday, December 11, 2025, 8:03 AM - 8:06 AM Location: 221 ABC Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2 - metastatic breast cancer (MBC) Hope M. Rugo, Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Paul Cottu, Marc Thill, Giuseppe Curigliano Author Affiliations: City of Hope Comprehensive Cancer Center, UPMC Hillman Cancer Center, The University of Texas MD Anderson Cancer Center, Pfizer, Université Paris Cité, Agaplesion Markus Krankenhaus, University of Milano, European Institute of Oncology, Flatiron Health Presentation Number: PS1-11-10 Poster Session 1: Wednesday, December 10, 2025, 12:30 PM - 2:00 PM Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024 Jane Meisel, Tim Pham, Clara Chen, Ayush Kris, James Roose Author Affiliations: Emory Winship Cancer Institute, AstraZeneca, Flatiron Health Presentation Number: PS2-02-04 Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021 - 2025) Sagar Sardesai, Meng Ru, Xinran Ma, Catherine Keane, Jingru Wang, Miguel Miranda, Xiaoqing Xu, Claudine Isaacs Author Affiliations: The Ohio State University Comprehensive Cancer Center, Lombardi Comprehensive Cancer Center, AstraZeneca, Flatiron Health Presentation Number: PS2-02-03 Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in patients with HR+/HER2 | metastatic breast cancer (MBC) who are overweight/obese Adam Brufsky, Neil M. Iyengar, Xianchen Liu, Benjamin Li, Doris Makari, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Vandana G. Abramson, Rachel M. Layman, Giuseppe Curigliano Author Affiliations: UPMC Hillman Cancer Center, Emory University School of Medicine, Pfizer, Vanderbilt University Medical Center, The University of Texas MD Anderson Cancer Center, University of Milano, European Institute of Oncology, Flatiron Health Presentation Number: PS2-04-12 Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, Flatiron Health continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. About Panoramic Data Panoramic data is Flatiron's foundational real-world data, flexibly designed to meet the needs of biopharma's evolving research priorities with biomarker depth, scaled outcomes, and longitudinal data across 5M+ patients. Panoramic data is a comprehensive data solution that spans disease settings and supports assessments of high priority subgroups of interest. Flatiron offers Panoramic data across solid tumors and hematologic malignancies to maximize use cases across oncology portfolios Contact Nina Toor [email protected] Posted in.